{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-26-000028","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2026-08-05T10:33:07+00:00","discovered_at":"2026-08-05T10:35:10.606177+00:00","generated_at":"2026-08-05T10:35:22.659997+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"United Therapeutics Reports Q2 2026 Revenue of $783.3M, Net Income Up 8% to $333M","bullets":["Total revenues decreased 2% year-over-year to $783.3M; net income rose 8% to $333.0M.","Tyvaso DPI revenues grew 4% to $326.6M; Nebulized Tyvaso fell 18% to $126.0M.","Submitted NDAs for ralinepag tablets in PAH and Nebulized Tyvaso in IPF; potential approvals in 2027.","Repurchased ~2.76M shares under $1.5B ASR agreements; $500M remaining in buyback program.","R&D expense increased 9% to $146.3M driven by cardiopulmonary projects and contingent consideration."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-26-000028","json":"https://secwatch.observer/filing/0001082554-26-000028.json","markdown":"https://secwatch.observer/filing/0001082554-26-000028.md","text":"https://secwatch.observer/filing/0001082554-26-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255426000028/0001082554-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255426000028/uthr-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T10:35:22.659997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}